Clinical-stage global biopharmaceutical company Zenas BioPharma Inc. (ZBIO) is positioned for a catalyst-rich stretch as it advances obexelimab, a bifunctional monoclonal antibody targeting CD19 and Fc?RIIb, through three late-stage trials.
The company expects topline results from its pivotal Phase 3 INDIGO trial in IgG4-related disease (IgG4-RD) around year-end 2025. This global, randomized, placebo-controlled study is the largest conducted to date in IgG4-RD and is designed to evaluate obexelimab's efficacy and safety in a population with no FDA-approved therapies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com